Report from Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report from Europe
Public-private R&D partnerships are on the rise across Europe, but national goals and academia-industry competition could prevent their success at the European level.


Pharmaceutical Technology
Volume 10, Issue 34, pp. 18-22

At the EU regional level, one of the most prominent collaborations in process development is a €30 million ($38 million) unit at the Bayer group's site at Leverkusen, Germany, which aims to create a modular continuous production plant. Among its 25 partners, in addition to Bayer, is AstraZeneca (London). Another partnership underway at London's Imperial College is coordinating an EU project involving nine partners from seven countries to develop a new generation of molecular purification technologies for the manufacture of active pharmaceutical ingredients.

However, the largest EU public-private partnership in pharmaceuticals–the €2 billion Innovative Medicines Initiative (IMI)—has already run into trouble because of disagreements over funding and IP rights among its academic and industrial participants. IMI, which launched its first projects two years ago, has been focusing on small-molecule R&D, but recently its scientific committee called for more attention be paid to biological-production processes. The university and research institute members of IMI complain that academia is being asked to pay too high a proportion of the project's direct costs, and that its industrial partners are being given too generous IP rights.

"The IMI model in its present form cannot be used as model for future [public-private partnerships] in EU programs," says Linda Polik, head of European research services at Oxford University, one of the IMI academic partners.

Nonetheless, these types of partnerships and other forms of industrial-academic research partnerships are continuing to gain strong support within the European pharmaceutical industry, particularly as the current economic climate puts pressure on the R&D funds of both the public and private sectors.

No matter how things turn out, BBSRC's Caulcott says, "This presents us with some great opportunities to work together through joint funding and sharing of knowledge and resources."

Sean Milmo is a freelance writer based in Essex, UK.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here